Skip to main content
Evidence Snapshot

Trypanosoma brucei rhodesiense

CHEMBL612348 ORGANISM Trypanosoma brucei rhodesiense
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:16:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612348
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Trypanosoma brucei rhodesiense as ChEMBL target CHEMBL612348. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Trypanosoma brucei rhodesiense
ORGANISM · Trypanosoma brucei rhodesiense
As of 2026-09-13
ChEMBL target ID
CHEMBL612348
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Trypanosoma brucei rhodesiense matters

As of 2026-09-13

Trypanosoma brucei rhodesiense is reviewed as Trypanosoma brucei rhodesiense; the current evidence base includes 62 approved drugs, 5446 compounds, and 784 assays, with lead potency reaching pChEMBL 10.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 62 approved drugs, 5446 compounds, and 784 assays for this target. The dominant activity type is IC50. CHEMBL467047 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL467047 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
62 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Trypanosoma brucei rhodesiense matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5446
Total Compounds
784
Total Assays
62
Approved Drugs
IC50: 5168.0, EC50: 371.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL467047
 10.0 IC50 —
No preferred name
CHEMBL4085387
 9.7 IC50 —
No preferred name
CHEMBL4066422
 9.3 IC50 —
No preferred name
CHEMBL2023963
 9.3 EC50 —
No preferred name
CHEMBL55
 9.2 EC50 Approved

Approved Drugs

Structure Compound First Approval
FEXINIDAZOLE
CHEMBL1631694
 2021
RIFAMYCIN
CHEMBL437765
 2018
IBANDRONIC ACID
CHEMBL997
 1996
SERTRALINE
CHEMBL809
 1991
PENTAMIDINE
CHEMBL55
 1984
PENTAMIDINE ISETHIONATE
CHEMBL361506
 1984
TIOCONAZOLE
CHEMBL1200438
 1983
NITROFURANTOIN
CHEMBL572
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:16:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612348